z-logo
Premium
Posaconazole in lung transplant recipients: use, tolerability, and efficacy
Author(s) -
Robinson C.L.,
Chau C.,
Yerkovich S.T.,
Azzopardi M.,
Hopkins P.,
Chambers D.
Publication year - 2016
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12497
Subject(s) - medicine , tolerability , tacrolimus , posaconazole , adverse effect , lung , lung transplantation , retrospective cohort study , transplantation , gastroenterology , surgery , antifungal , itraconazole , dermatology
Background Fungal infection is a common cause of mortality and morbidity in lung transplant recipients (Lu TR ). Treatment failure to first‐line antifungals because of resistance or intolerance is an increasing problem. Posaconazole ( PCZ ), a triazole antifungal, is an attractive treatment option. Methods We performed a single‐center retrospective study to describe the use, tolerability, efficacy, and drug interaction effect (with tacrolimus) of PCZ oral suspension in Lu TR . Results Seventy‐eight patients were treated with PCZ oral suspension for prophylaxis ( n = 15), pre‐emptive treatment ( n = 31), and treatment of possible ( n = 7) and probable ( n = 25) invasive fungal infection. A range of fungal isolates was encountered. Resolution was observed in 52.4% (probable, possible, and pre‐emptive treatment groups). Aggregate all‐cause 1‐year mortality was 12.8%. PCZ was well tolerated with 11.5% of patients experiencing adverse effects. Despite dose adjustment strategies, 11.7% of patients experienced supratherapeutic tacrolimus levels, which in 5 cases was associated with a rise (mean 21.6 μmol/L) in serum creatinine. Conclusions PCZ is well tolerated and appears effective in the management of fungal infection after lung transplantation. Patients receiving concurrent tacrolimus require careful therapeutic drug monitoring.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here